Drug profile · INN
dacomitinib hydrate
VIZIMPRO
dacomitinib hydrate (VIZIMPRO) is a epidermal growth factor receptor erbb1 inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — dacomitinib hydrate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.78
Quick answer
dacomitinib hydrate (VIZIMPRO) is a epidermal growth factor receptor erbb1 inhibitor.
Key facts
INN dacomitinib hydrate
Brand VIZIMPRO
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Target Epidermal growth factor receptor
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dacomitinib hydrate?
dacomitinib hydrate (VIZIMPRO) is a epidermal growth factor receptor erbb1 inhibitor.
What is the brand name for dacomitinib hydrate?
VIZIMPRO is a marketed brand name for dacomitinib hydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.